Abstract
The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Current Topics in Medicinal Chemistry
Title: Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands
Volume: 2 Issue: 6
Author(s): Richard B. Westkaemper and Richard A. Glennon
Affiliation:
Keywords: Receptor Mutagenesis, Pharmacophore Models, Tricyclic Ring System, AMDA Analogs, aminomethyl rotation
Abstract: The present review describes our approach to the development of a structurally unique class of 5- HT2A ligands. On the basis of an abbreviated graphics model of a 5-HT2A serotonin receptor, it was hypothesized that introduction of an additional aromatic ring might enhance the affinity of phenylethylamine (an agent that lacks significant affinity for the 5-HT2A receptors). Continued work with such structures, and the continual refinement of graphics receptor models, ultimately led to the identification of AMDA (27, 5-HT2A Ki = 20 nM). AMDA is a 5-HT2A antagonist that, unlike certain other tricyclic 5-HT2A antagonists, binds with very low affinity at dopamine D2 receptors, the serotonin transporter, and the norepinephrine transporter. Comparative structure-affinity studies indicate that AMDA binds in a manner distinct from the tricyclic antagonists Graphics models were employed to identify possible modes of binding. This investigation illustrates the impact of a combination of classical medicinal chemistry, receptor modeling, and molecular biology on novel drug design.
Export Options
About this article
Cite this article as:
Westkaemper B. Richard and Glennon A. Richard, Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New class of 5-HT2A Ligands, Current Topics in Medicinal Chemistry 2002; 2 (6) . https://dx.doi.org/10.2174/1568026023393741
DOI https://dx.doi.org/10.2174/1568026023393741 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ginsenosides from the Leaves and Flower Buds of Panax ginseng and their Pharmacological Effects
Current Bioactive Compounds A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Flavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Novel Strategies in Drug Discovery of the Calcium-Sensing Receptor Based on Biased Signaling
Current Drug Targets Tribute to Prof. Gerald Farin: Remembering A Geometric Modeling Researcher and Educator
Neuroscience and Biomedical Engineering (Discontinued) First Episode Psychosis, Substance Abuse and Prognosis: A Systematic Review
Current Psychiatry Reviews Serum Tryptophan, Tryptophan Catabolites and Brain-derived Neurotrophic Factor in Subgroups of Youngsters with Autism Spectrum Disorders
CNS & Neurological Disorders - Drug Targets Colon Targeted Press Coated Tablets of Venlafaxine Hydrochloride for Treatment of Depression
Current Psychopharmacology Screening the Receptorome Yields Validated Molecular Targets for Drug Discovery
Current Pharmaceutical Design Recent Developments in CE-MS Based Metabolomics
Current Analytical Chemistry Parallel Solution-Phase Synthesis of a 2-Aminothiazole Library Including Fully Automated Work-Up
Combinatorial Chemistry & High Throughput Screening Sepsis and Solid Organ Transplantation
Current Drug Targets β-Amyloid, Neuronal Death and Alzheimers Disease
Current Molecular Medicine Zebrafish: Predictive Model for Targeted Cancer Therapeutics from Nature
Current Cancer Drug Targets Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Improving Cognition through Dance in Older Filipinos with Mild Cognitive Impairment
Current Alzheimer Research Implication of Circadian Rhythms and Melatonin in Major Depressive Disorder: The Evidence Base for New Antidepressant Treatment
Current Psychiatry Reviews Post Fusion MRI Artifacting - An In Vitro Study of Defined Intervertebral Test Spacers
Current Medical Imaging